CytoTools AG Stock
€0.54
Your prediction
CytoTools AG Stock
Pros and Cons of CytoTools AG in the next few years
Pros
Cons
Performance of CytoTools AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CytoTools AG | -16.300% | 0.000% | 48.352% | -75.455% | -29.870% | -96.860% | -94.387% |
| Nanorepro AG | -5.280% | 9.222% | 5.278% | -11.449% | -8.010% | -79.840% | 57.917% |
| Heidelberg Pharma AG | -2.970% | 1.000% | -1.623% | -26.812% | -17.663% | -58.943% | -3.195% |
| Vivoryon Therapeutics N.V. | -10.770% | 113.615% | 69.460% | -93.299% | -88.682% | -93.583% | -95.758% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Taking a first glance at CytoTools' financial statements provides an intriguing snapshot of the company's financial health and positions within the Biotechnology & Medical Research industry. As with many companies in this sector, CytoTools appears to be in a phase where significant investment in research and development is normal behavior, although this often comes with the challenge of sustained profitability and cash flow generation.
The company's balance sheets from 2020 to 2022 show a rather robust total asset base with a marked increase from around €18 million in 2021 to over €21 million in 2022. Notably, in 2022, a substantial portion of CytoTools' assets is not in the form of intangible assets, which is typical for firms in biotechnology, reflecting significant investment in intellectual property. Equity has also risen accordingly, while liabilities remain relatively marginal. This suggests a solid balance sheet with potentially low solvency risk.
*Pros: *
